Das deutsche Lipoproteinaphereseregister (DLAR) – Was sind die Hintergründe?

Zusammenfassung

Ein von dem Gemeinsamen Bundesausschuss (G-BA) für Patienten mit schwerer LDL-Cholesterin- oder isolierter Lipoprotein(a)-Erhöhung und kardiovaskulären Ereignissen unter chronischer Lipoproteinapherese (LA) gefordertes Register wurde aufgebaut. Als Deutsches Lipoproteinaphereseregister (DLAR) ist es seit April 2012 im Routinebetrieb, in das alle Patienten, die regelmäßig mit einem Lipoproteinaphereseverfahren therapiert werden, erfasst werden sollen. Dieses Register wird von dem neutralen Träger Wissenschaftliches Institut für Nephrologie (WiNe) vertreten. WiNe hat einen wissenschaftlichen Beirat eingerichtet und diesen beauftragt, die Daten- und Behandlungsqualität zu überwachen und in jährlichen Abständen eine Auswertung dieser Daten zu erstellen. Ziel des DLAR ist nicht nur die Erfassung der Lipidparameter vor und nach Apheresebehandlungen als Qualitätssicherungskriterium, sondern auch z. B. die prospektive Erfassung von Nebenwirkungen, kardiovaskulären Ereignissen bei Patienten vor und unter chronischer Lipoproteinapherese.

Summary

The Federal Joint Committee (G-BA), a paramount decision-making body of the German Healthcare System, issued to build up a registry for patients suffering from severe increases of LDL cholesterol or lipoprotein(a) (Lp(a)) levels with severe progress of cardiovascular diseases undergoing regular lipoprotein apheresis (LA) treatment. Since April 2012, the „Deutsche Lipoproteinaphereseregister (DLAR)” works in routine operation, in which all patients undergoing regular LA treatment should be documented. The German institution „Wissenschaftliches Institut für Nephrologie (WiNe)” is responsible for the registry arrangement and data assessment. Therefore, WiNe has established an interdisciplinary advisory board. This board has to monitor the quality of data and LA treatments and has to issue a registry report in yearly intervals. The aim of DLAR is not only to record lipid data before and after apheresis sessions as quality criteria but also e. g. to prospectively register treatment side effects, cardiovascular events in these patients before LA treatment was initiated and during chronic LA treatment.

Key words

lipoprotein apheresis - registry - cardiovascular events - low-density lipoprotein (LDL) - lipoprotein(a) (Lp(a))

• Literatur

• 1 Thompson GR. HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198: 247-255
• 2 Schettler V, Neumann CL, Hulpke-Wette M et al. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl 2012; 7: 15-19
• 3 Perk J, De Backer G, Gohlke H et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701
• 4 Gemeinsamer Bundesausschuss (G-BA). Dokumentationsvorgaben zur Indikationsstellung der Lp(a)-Apherese (vertragsärztliche Versorgung). Im Internet: http://www.g-ba.de Stand: 07.11.2013
• 5 Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008; 117: 176-184
• 6 Bennet A, Di Angelantonio E, Erqou S et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008; 168: 598-608
• 7 Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-2528
• 8 Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853
• 9 Jaeger BR, Richter Y, Nagel D et al. Group of Clinical Investigators. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6: 229-239
• 10 Schettler V, Jaeger BR, Klingel R. German apheresis working group. The German Lipid Apheresis Registry - remaining to be established. Atheroscler Suppl 2009; 10: 59-61
• 11 Leebmann J, Röseler E, Julius U et al. for the Pro(a)LiFe-study group. Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2009; Sep 20 [Epub ahead of print]
• 12 von Dryander M, Fischer S, Passauer J et al. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 2013; 14: 39-44
• 13 Stegmayr B, Ptak J, Wikstrom B et al. World apheresis registry 2003-2007 data. Transfus Apher Sci 2008; 39: 247-254
• 14 Wissenschaftliches Institut für Nephrologie (WiNe).